16Feb

New Multiplex Real-time PCR Kits Detect Clinically Relevant β-lactamase Genes

β-lactamase enzymes inactivate β-lactam antibiotics and render them ineffective for the treatment of clinically-important Gram-negative bacterial infections. Now, two new kits from Streck Inc., available in the UK from Alpha Laboratories Ltd., provide a comprehensive, cost-effective molecular method to detect the most clinically-important β-lactamases that confer resistance to penicillins, cephamycins, and in some cases, carbapenems. 

The antibiotic resistance monitoring and detection (ARM-D) kits, are multiplex real-time PCR kits that can quickly detect more than 450 β-lactamase gene variants.

The ARM-D® Kit, β-Lactamase detects 9 different Carbapenemases, ESBLs and plasmid-mediated ampC gene families. The ARM-D® Kit, ampC targets 6 plasmid-mediated ampC resistance gene families and can differentiate plasmid-mediated ampC β-lactamase resistance from chromosomal resistance.

These genotypic detection methods identify the most prevalent types of β-lactamase-based antibiotic resistance and complement phenotypic methods for the detection of multidrug resistant organisms. They can be used with standard susceptibility tests to improve surveillance and epidemiologic tracking, for improved infection control and increased effectiveness of antibiotic stewardship programs.

AmpC β-lactamases are chromosomally encoded in many bacterial species. Their overexpression can lead to resistance to most β-lactam antibiotics, causing therapeutic failure. Transmissible plasmids with acquired genes for AmpC β-lactamases often cause increased β-lactamase production and can appear in organisms lacking or having low-level expression of a chromosomal ampC gene. Resistance due to plasmid-mediated AmpC enzymes can be broad in spectrum and often hard to detect. As Gram-negative organisms producing multiple or plasmid-mediated β-lactamases are difficult to identify phenotypically, more specific detection methods are essential for the identification of clinically important β-lactamases and selection of the appropriate antibiotic therapy. Detection and genetic identification of both plasmid-mediated and chromosomally expressed AmpC β-lactamases are crucial for better understanding of these resistance mechanisms and, consequently, for active surveillance and infection control.

Please visit www.alphalabs.co.uk  for further information or contact Alpha Laboratories on 0800 38 77 32 or email marketing@alphalabs.co.uk 

Related

OGT expands direct sales and support infrastructure in Europe

Customers to benefit from Sysmex’s extensive operational footprint

Read More >

MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated I...

Read More >

SpeeDx Receives CE-IVD Mark for ResistancePlus® GC

New molecular assay enables rapid antibiotic resistance result to support use of cost effective and ...

Read More >

BBI Solutions demonstrates internal antibody development capabilities while expanding their infectious disease reagent suite

BBI Solutions has released four new antibodies specific for the HIV-1 p24 capsid protein. The antibo...

Read More >

Novodiag® Bacterial GE+, a new diagnostic test for on-demand detection of bacterial pathogens

Espoo, Finland, April 17th, 2018 - Mobidiag, a Finnish molecular diagnostics company, today announce...

Read More >

OGT launches enhanced SureSeq™ Interpret NGS analysis software

Powerful, flexible and easy-to-use analysis solution gets the most out of NGS data

Read More >